Venlafaxine

also known as Effexor · Venlafaxine XR · Venlafaxine hydrochloride · venlafaxine extended release · EFFEXOR XR · Efexor XR · venlafaxine ER · venlafaxine extended release (XR) · +12 more

Small molecule

Developed for: major depressive disorder · depressive disorder · anxiety disorder · bipolar disorder · chronic pain syndrome · bipolar depression · generalized anxiety disorder · panic disorder
+38 more
· spinal cord injury · anxiety · breast cancer · chemotherapy-induced neuropathy · dysthymic disorder · neuropathy, painful · obstructive sleep apnea syndrome · prostate cancer · social phobia · somatoform disorder · alcohol-related disorders · aphasia · bipolar II disorder · body dysmorphic disorder · cocaine dependence · diabetic neuropathy · dyspepsia · fibromyalgia · head and neck squamous cell carcinoma · interstitial cystitis · ischemic stroke · Meniere disease · osteoarthritis · osteoarthritis, knee · peripheral neuropathy · post-traumatic stress disorder · postherpetic neuralgia · rheumatoid arthritis · sleep disorder · traumatic brain injury · Alzheimer disease · cannabis dependence · gallbladder disorder · migraine disorder · mixed anxiety and depressive disorder · obsessive-compulsive disorder · substance withdrawal syndrome · traumatic neuropathy
Investigated by: Wyeth is now a wholly owned subsidiary of Pfizer · National Institute of Mental Health (NIMH) · New York State Psychiatric Institute · Teva Pharmaceuticals USA · University of Pittsburgh · Eli Lilly and Company
+106 more
· Massachusetts General Hospital · Mayo Clinic · Beijing Tiantan Hospital · Centre for Addiction and Mental Health · Indiana University · National Cancer Institute (NCI) · University of Michigan · University of Pennsylvania · Viatris Inc. · Boehringer Ingelheim · Dr. Inge Winter · Ontario Mental Health Foundation · Samsung Medical Center · U.S. Department of Education · University of Alabama at Birmingham · University of Münster · University of Washington · Vanderbilt University · Actavis Inc. · Ain Shams University · Ajay Wasan, MD, Msc · All India Institute of Medical Sciences, Bhubaneswar · Alliance for Clinical Trials in Oncology · American Hearing Research Foundation · American Thoracic Society · Anhui Medical University · AstraZeneca · Baylor Health Care System · Bayne-Jones Army Community Hospital · Beijing Jianjia Rehabilitation Hospital · Beijing Sanbo Brain Hospital · Boston Medical Center · Cairo University · Central Hospital, Nancy, France · Centre Hospitalier Universitaire Vaudois · China Medical University Hospital · Cures Within Reach · Department of Health, Executive Yuan, R.O.C. (Taiwan) · Dr. Nazanin Alavi · Dr. Reddy's Laboratories Limited · First Affiliated Hospital of the Chinese People's Liberation Army Naval Medical University · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · French National Institute of Health and Medical Research · General Hospital of Ningxia Medical University · German Federal Ministry of Education and Research · GlaxoSmithKline · Guangdong Provincial Hospital of Chinese Medicine, Zhuhai · Guangzhou General Hospital of Guangzhou Military Command · Hannover Medical School · HolsboerMaschmeyer NeuroChemie GmbH · Hospices Civils de Lyon · Icahn School of Medicine at Mount Sinai · Jilin Provincial People's Hospital · K. Lieb · Max-Planck-Institute of Psychiatry · McMaster University · Medical University of South Carolina · Medical University of Vienna · Medtronic - MITG · Mendel AI · Mit Ghamr Oncology Center · National Cheng-Kung University Hospital · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · National Institute on Alcohol Abuse and Alcoholism (NIAAA) · National Institute on Drug Abuse (NIDA) · National Institutes of Health (NIH) · Neuropsychiatric Research Institute, Fargo, North Dakota · New York University · North Dakota State University · Novartis Pharmaceuticals · Online PsychoTherapy Clinic · Orthopedic Research and Education Foundation · Otsuka Pharmaceutical Development & Commercialization, Inc. · all 112 on the full record

Regulatory milestones approvals, filings & regulatory actions · 8 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (7)	US (FDA)	EFFEXOR XR	—	1999-03-11 – 2007-12-14	fda.gov ↗
Approved	US (FDA)	EFFEXOR	—	1993-12-28	fda.gov ↗

Trials 110 · started per year

today

US approved 1993

1993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 114 trials · 3 met primary
Phase 1	NCT07698626	Dec 2026 → Dec 2027 expected	chronic pain syndrome, interstitial cystitis	Beijing Tiantan Hospital	Not yet recruiting	No outcome recorded
Phase 1	NCT02637193	Dec 2015 → Jul 2016	—	Viatris Inc.	Completed	No outcome recorded
Phase 1	NCT01867255	Oct 2013 → Mar 2015	—	Mayo Clinic	Completed	No outcome recorded
Phase 1	NCT01350921	May 2011 → Mar 2012	—	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT01235338	Oct → Dec 2010	—	Shire	Completed	No outcome recorded
Phase 1	NCT00362271	Aug → Sep 2006	—	Otsuka Pharmaceutical Development & Commercialization, Inc.	Completed	No outcome recorded
Phase 1	NCT01512459	May 2006	—	Dr. Reddy's Laboratories Limited	Completed	No outcome recorded
Phase 1	NCT00871364	Apr → May 2006	—	Actavis Inc.	Completed	No outcome recorded
Phase 1	NCT01282814	Feb → Mar 2003	—	Teva Pharmaceuticals USA	Completed	Met primary
Phase 1	NCT00834964	Dec 2002	—	Teva Pharmaceuticals USA	Completed	Met primary
Phase 1	NCT00834249	Dec 2002	—	Teva Pharmaceuticals USA	Completed	No outcome recorded
Phase 1	NCT01282801	Sep → Oct 2002	—	Teva Pharmaceuticals USA	Completed	No outcome recorded
Phase 1	NCT01260896	Sep → Oct 2002	—	Teva Pharmaceuticals USA	Completed	Met primary
Phase 1	NCT00745017	Jul 2001 → Jul 2006	major depressive disorder	Centre for Addiction and Mental Health	Completed	No outcome recorded

Phase 213 trials · 1 met primary · 2 missed
Phase 2	NCT07497282	Mar → Oct 2026 expected	rheumatoid arthritis	Ain Shams University	Not yet recruiting	No outcome recorded
Phase 2	NCT07330648	Oct 2025 → Jan 2027 expected	generalized anxiety disorder	Anhui Medical University	Recruiting	No outcome recorded
Phase 2	NCT05724849	Aug 2023 → Aug 2026	depressive disorder, head and neck cancer	Vanderbilt University Medical Center	Withdrawn	No outcome recorded Stop: Business
Phase 2	NCT04639193	Dec 2020 → Jan 2022	obstructive sleep apnea syndrome	University of California, San Diego	Completed	Met primary
Phase 2	NCT04437485	Oct 2020 → Aug 2022	dysthymic disorder, major depressive disorder, prediabetes syndrome, type 2 diabetes mellitus	Indiana University	Completed	Missed primary
Phase 2	NCT03574792	May 2018 → Apr 2021	head and neck squamous cell carcinoma	Roswell Park Cancer Institute	Completed	No outcome recorded
Phase 2	NCT01533753	Feb 2012 → Jan 2014	prostate cancer	University of Wisconsin, Madison	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00742573	Aug 2008 → Jan 2014	major depressive disorder	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 2	NCT00620776	Oct 2006 → Mar 2008	generalized anxiety disorder	University of Pennsylvania	Completed	Missed primary
Phase 2	NCT00744406	Jul 2003 → Sep 2006	major depressive disorder	Centre for Addiction and Mental Health	Completed	No outcome recorded
Phase 2	NCT00198250	May 2000 → Nov 2005	breast cancer	Indiana University	Completed	No outcome recorded
Phase 2	NCT00249483	Oct 1999 → Feb 2005	cocaine dependence	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 2	NCT00001483	Jun 1995 → May 2002	bipolar disorder, depressive disorder	National Institute of Mental Health (NIMH)	Completed	No outcome recorded

Phase 2/36 trials · 1 met primary · 1 missed
Phase 2/3	NCT04747314	Mar 2021 → Nov 2024	anxiety, chronic pain syndrome	Ajay Wasan, MD, Msc	Completed	No outcome recorded
Phase 2/3	NCT04737967	Feb → Aug 2021	chemotherapy-induced neuropathy	Mendel AI	Unknown	No outcome recorded
Phase 2/3	NCT04218123	Feb 2020 → Sep 2023	Meniere disease	Medical University of South Carolina	Completed	Missed primary
Phase 2/3	NCT00080158	Mar 2004 → Jun 2007	depressive disorder	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 2/3	NCT00248612	Sep 2003 → Mar 2009	alcohol-related disorders, anxiety disorder	Boston Medical Center	Completed	No outcome recorded
Phase 2/3	NCT00018902	Jan 2001 → Mar 2007	depressive disorder	University of Pittsburgh	Completed	Met primary
Phase 319 trials · 4 met primary · 4 missed
Phase 3	NCT05603104	Apr 2025 → Jun 2028 expected	bipolar depression, major depressive disorder, schizophrenia	Dr. Inge Winter	Recruiting	No outcome recorded
Phase 3	NCT05973786	Feb 2025 → Jun 2028 expected	bipolar depression	Dr. Inge Winter	Recruiting	No outcome recorded
Phase 3	NCT06106529	Oct 2024 → Jan 2029 expected	female breast carcinoma	Reinier de Graaf Groep	Recruiting	No outcome recorded
Phase 3	NCT02374567	Jan 2015 → Jun 2017	anxiety disorder, dementia, depressive disorder, schizophrenia +1	Hannover Medical School	Terminated	No outcome recorded
Phase 3	NCT01485887	Jan 2012 → Jan 2014	major depressive disorder	Viatris Inc.	Completed	Mixed
Phase 3	NCT01441440	Nov 2011 → Mar 2014	major depressive disorder	Viatris Inc.	Completed	Mixed
Phase 3	NCT00354432	Feb 2007 → Aug 2010	prostate cancer	Wake Forest University Health Sciences	Terminated	Missed primary
Phase 3	NCT00329186	May 2006 → Jun 2007	—	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00122837	Apr 2005 → Jan 2007	anxiety disorder	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT00195598	Jan 2005 → Apr 2006	panic disorder	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00122850	Oct 2004 → Nov 2005	anxiety disorder	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT01011751	Apr 2004 → Dec 2007	prostate adenocarcinoma	Takeda	Completed	Met primary
Phase 3	NCT00179283	Apr 2002 → Apr 2003	major depressive disorder	Vanderbilt University	Completed	Missed primary
Phase 3	NCT00030914	Apr 2002 → Feb 2006	—	Alliance for Clinical Trials in Oncology	Completed	Met primary
Phase 3	NCT00044772	Nov 2001 → Apr 2003	panic disorder	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00043550	Nov 2001 → Jun 2009	major depressive disorder	University of Pennsylvania	Completed	Missed primary
Phase 3	NCT00038896	Apr 2001 → Dec 2002	panic disorder	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	Missed primary
Phase 3	NCT00238719	Dec 1999 → Jun 2003	social phobia	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00087737	? → May 2005	major depressive disorder	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded

Phase 442 trials · 4 met primary · 3 missed
Phase 4	NCT07795593	Oct 2026 → May 2031 expected	diabetic kidney disease, diabetic neuropathy	University of Michigan	Not yet recruiting	No outcome recorded
Phase 4	NCT06803485	Mar 2025 → Aug 2026 overdue	somatoform disorder	All India Institute of Medical Sciences, Bhubaneswar	Recruiting	No outcome recorded
Phase 4	NCT06295562	Nov 2024 → Oct 2025	obstructive sleep apnea syndrome	China Medical University Hospital	Completed	No outcome recorded
Phase 4	NCT04977271	Jan → Oct 2024	depressive disorder, head and neck cancer	University of Alabama at Birmingham	Withdrawn	No outcome recorded
Phase 4	NCT05875610	May → Oct 2023	chemotherapy-induced neuropathy	Mit Ghamr Oncology Center	Unknown	No outcome recorded
Phase 4	NCT06131268	Mar 2022 → Mar 2024	bipolar depression, major depressive disorder	Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico	Unknown	No outcome recorded
Phase 4	NCT05023278	May 2021 → Feb 2025	chronic pain syndrome, neuropathy, painful, osteoarthritis, knee	University of California, San Francisco	Completed	No outcome recorded
Phase 4	NCT04207385	Dec 2019 → Aug 2021	depressive disorder	Xijing Hospital	Unknown	No outcome recorded
Phase 4	NCT02433353	Jan 2016	post-traumatic stress disorder	Bayne-Jones Army Community Hospital	Withdrawn	No outcome recorded
Phase 4	NCT02711215	May 2015 → Jan 2020	major depressive disorder	Medical University of Vienna	Unknown	No outcome recorded
Phase 4	NCT02051413	Feb 2014 → May 2018	major depressive disorder	French National Institute of Health and Medical Research	Completed	No outcome recorded
Phase 4	NCT02005107	Dec 2013 → Mar 2015	—	North Dakota State University	Completed	No outcome recorded
Phase 4	NCT01796132	Aug 2012 → Dec 2016	depressive disorder, lactation disease	Centre Hospitalier Universitaire Vaudois	Unknown	No outcome recorded
Phase 4	NCT01436643	Nov 2011 → Sep 2013	depressive disorder, relapsing-remitting multiple sclerosis	Novartis Pharmaceuticals	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT02237937	Sep 2011 → Dec 2014	major depressive disorder	HolsboerMaschmeyer NeuroChemie GmbH	Unknown	No outcome recorded
Phase 4	NCT01124188	May 2010 → Feb 2016	depressive disorder	University of Pittsburgh	Completed	Missed primary
Phase 4	NCT00974155	Sep 2009 → May 2014	major depressive disorder	K. Lieb	Completed	No outcome recorded
Phase 4	NCT00892047	Aug 2009 → Sep 2014	depressive disorder	University of Pittsburgh	Completed	Met primary
Phase 4	NCT00211809	Sep 2008 → Jun 2009	body dysmorphic disorder	Icahn School of Medicine at Mount Sinai	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT00634283	Feb 2008 → Feb 2009	depressive disorder	University of California, Los Angeles	Completed	Missed primary
Phase 4	NCT00602537	Dec 2007 → Jun 2013	bipolar disorder, depressive disorder	University of Pennsylvania	Completed	No outcome recorded
Phase 4	NCT00592384	Jul 2007 → Sep 2012	dysthymic disorder, major depressive disorder, spinal cord injury	University of Washington	Completed	Mixed
Phase 4	NCT00474708	Apr 2007 → Mar 2008	major depressive disorder	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 4	NCT01204086	Mar 2007 → Dec 2010	major depressive disorder	National Cheng-Kung University Hospital	Unknown	No outcome recorded
Phase 4	NCT00401726	Jun 2006 → Oct 2007	major depressive disorder	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	Missed primary
Phase 4	NCT00282828	Mar 2006 → Dec 2011	social phobia	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT00205491	Oct 2004 → Sep 2007	traumatic brain injury	Virginia Commonwealth University	Completed	No outcome recorded
Phase 4	NCT00118430	Sep 2004 → Jul 2008	depressive disorder	Indiana University	Completed	Met primary
Phase 4	NCT00316160	Sep 2004 → May 2005	major depressive disorder	GlaxoSmithKline	Completed	Met primary
Phase 4	NCT00611676	Sep 2004 → Feb 2007	osteoarthritis	University of Washington	Completed	No outcome recorded
Phase 4	NCT00546923	Aug 2004 → Jun 2006	anxiety disorder, depressive disorder	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 4	NCT00546494	Feb 2004 → Mar 2005	depressive disorder	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 4	NCT00071695	Jul 2003 → May 2004	depressive disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00157547	Apr 2003 → Aug 2006	major depressive disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT00067912	Apr 2003 → Mar 2004	major depressive disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00641927	Apr 2002 → Oct 2006	bipolar II disorder	Stanley Medical Research Institute	Completed	No outcome recorded
Phase 4	NCT00188643	Jan 2002 → Jan 2007	bipolar disorder	University Health Network, Toronto	Completed	No outcome recorded
Phase 4	NCT00177567	Jul 2001 → Jan 2004	bipolar disorder	University of Pittsburgh	Completed	No outcome recorded
Phase 4	NCT00021528	Jul 2001 → Sep 2006	major depressive disorder	National Institute of Mental Health (NIMH)	Completed	No outcome recorded
Phase 4	NCT00045916	Feb 2001 → Dec 2006	bipolar disorder, depressive disorder	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 4	NCT00177528	Oct 2000 → Nov 2004	depressive disorder	University of Pittsburgh	Completed	No outcome recorded
Phase 4	NCT00046020	Aug 2000 → Oct 2005	major depressive disorder	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	Met primary

Phase not applicable16 trials · 1 met primary · 3 missed
—	NCT07361796	Dec 2025 → Sep 2027 expected	herpes zoster, postherpetic neuralgia	Beijing Tiantan Hospital	Recruiting	No outcome recorded
—	NCT07186751	Sep 2025 → Jun 2027 expected	fibromyalgia	Beijing Tiantan Hospital	Recruiting	No outcome recorded
—	NCT04478526	Apr 2020 → May 2021	generalized anxiety disorder	Dr. Nazanin Alavi	Completed	No outcome recorded
—	NCT03588572	Aug 2018 → Jul 2019	aphasia, ischemic stroke	Guangzhou General Hospital of Guangzhou Military Command	Completed	No outcome recorded
—	NCT02955719	Mar 2016 → Jul 2020	anxiety, cognitive impairment with or without cerebellar ataxia, depressive disorder	Centre for Addiction and Mental Health	Completed	No outcome recorded
—	NCT01611155	Feb 2012 → Mar 2014	peripheral neuropathy	Mayo Clinic	Completed	Missed primary
—	NCT01000623	Jan 2010 → Feb 2012	—	Mayo Clinic	Completed	No outcome recorded
—	NCT00735670	Jun 2008 → Jun 2012	spinal cord injury	University of Michigan	Completed	Missed primary
—	NCT00386243	Dec 2007 → May 2012	chronic pain syndrome	VA Office of Research and Development	Completed	Met primary
—	NCT00115362	Jul 2005 → Jul 2007	dyspepsia	Radboud University Medical Center	Completed	No outcome recorded
—	NCT00167856	Jun 2005 → Aug 2007	neuropathy, painful, spinal cord injury	US Department of Veterans Affairs	Completed	Missed primary
—	NCT00084669	May 2004 → Oct 2007	breast cancer, sleep disorder	Massachusetts General Hospital	Completed	No outcome recorded
—	NCT00057642	Sep 2002 → Aug 2006	depressive disorder	New York State Psychiatric Institute	Completed	No outcome recorded
—	NCT00186264	Aug 2002 → Apr 2006	major depressive disorder	Stanford University	Completed	No outcome recorded
—	NCT01352572	Jan 2002 → Dec 2018	depressive disorder	Samsung Medical Center	Unknown	No outcome recorded
—	NCT01352559	Nov 2001 → Mar 2007	depressive disorder	Samsung Medical Center	Unknown	No outcome recorded

Comparator or background therapy88 trials
Phase 1	NCT03274817 Comparator	Jun 2009 → Sep 2019	Alzheimer disease	NYU Langone Health	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT00727064 Comparator	Jun → Aug 2008	—	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 1	NCT00676039 Comparator	Nov 2007 → Jul 2008	—	University of Ottawa	Completed	No outcome recorded
Phase 1/2	NCT05884268 Comparator	May 2023 → Jan 2024	gallbladder disorder	Mansoura University	Unknown	No outcome recorded
Phase 1/2	NCT02181231 Background	Jun 2016 → Apr 2018	major depressive disorder	Washington University School of Medicine	Completed	No outcome recorded
Phase 1/2	NCT02263248 Background	Dec 2014 → Jan 2017	major depressive disorder	Centre for Addiction and Mental Health	Completed	No outcome recorded
Phase 1/2	NCT02451475 Comparator	Feb 2013 → Sep 2014	fibromyalgia	Mansoura University	Completed	No outcome recorded
Phase 1/2	NCT00612807 Background	Jul 2006 → Jun 2010	major depressive disorder	Duke University	Completed	No outcome recorded
Phase 2	NCT04653337 Background	Sep 2020 → Dec 2023	depressive disorder	Xijing Hospital	Unknown	No outcome recorded
Phase 2	NCT04539951 Comparator	Sep 2020 → Jun 2027 expected	obsessive-compulsive disorder	Shanghai Mental Health Center	Recruiting	No outcome recorded
Phase 2	NCT03321526 Background	Dec 2017 → Jun 2019	major depressive disorder	Janssen Research & Development, LLC	Completed	Missed primary
Phase 2	NCT01716377 Comparator	Oct 2012 → Sep 2016	—	Rhode Island Hospital	Completed	No outcome recorded
Phase 2	NCT01435759 Background	May 2011 → Jan 2014	major depressive disorder	Shire	Completed	Missed primary
Phase 2	NCT01114698 Comparator	Mar 2011 → Jan 2012	depressive disorder	Janssen Research & Development, LLC	Terminated	No outcome recorded Stop: Business
Phase 2	NCT00967707 Comparator	Aug 2009 → Apr 2011	traumatic neuropathy	Uppsala University	Completed	No outcome recorded
Phase 2	NCT00854100 Background	Jun 2009 → Dec 2010	major depressive disorder	Forest Laboratories	Completed	Missed primary
Phase 2	NCT00584974 Comparator	Dec 2007 → May 2009	major depressive disorder	Sumitomo Pharma America, Inc.	Completed	No outcome recorded
Phase 2	NCT00448058 Comparator	Apr 2007 → Dec 2008	depressive disorder	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00131456 Comparator	Mar 2004 → Dec 2010	cannabis dependence, depressive disorder	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 2/3	NCT01977378 Comparator	Oct 2013 → Sep 2014	major depressive disorder	Jiangsu Hansoh Pharmaceutical Co., Ltd.	Unknown	No outcome recorded
Phase 3	NCT07296770 Background	Oct 2026 → Dec 2028 expected	chronic pain syndrome	University of California, San Francisco	Not yet recruiting	No outcome recorded
Phase 3	NCT04973930 Comparator	Mar 2022 → Dec 2025	breast cancer, major depressive disorder	New York State Psychiatric Institute	Suspended	No outcome recorded Stop: Enrollment
Phase 3	NCT05104918 Comparator	Feb → Apr 2022	major depressive disorder	Scotmann Pharmaceuticals	Unknown	No outcome recorded
Phase 3	NCT03434041 Background	May 2018 → Apr 2021	major depressive disorder	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 3	NCT02493868 Background	Oct 2015 → Feb 2018	major depressive disorder	Janssen Research & Development, LLC	Completed	Met primary
Phase 3	NCT02417064 Background	Aug 2015 → Feb 2018	—	Janssen Research & Development, LLC	Completed	Missed primary
Phase 3	NCT02418585 Background	Aug 2015 → Jun 2017	—	Janssen Research & Development, LLC	Completed	Met primary
Phase 3	NCT02400346 Background	Mar 2015 → Jun 2016	major depressive disorder	H. Lundbeck A/S	Completed	No outcome recorded
Phase 3	NCT01838681 Background	Jun 2013 → Jun 2016	major depressive disorder	H. Lundbeck A/S	Completed	Missed primary
Phase 3	NCT01838876 Background	Apr 2013 → Jul 2015	major depressive disorder	Forest Laboratories	Completed	No outcome recorded
Phase 3	NCT02086929 Comparator	Dec 2012 → Apr 2014	major depressive disorder	Angelini Pharma	Completed	No outcome recorded
Phase 3	NCT01715805 Background	Nov 2012 → Jun 2016	major depressive disorder	Forest Laboratories	Completed	Missed primary
Phase 3	NCT01571453 Comparator	May 2012 → Oct 2013	major depressive disorder	H. Lundbeck A/S	Completed	Met primary
Phase 3	NCT02179268 Comparator	Mar 2012 → Apr 2014	osteoporosis	Guiyang Medical University	Completed	No outcome recorded
Phase 3	NCT01557712 Background	Mar 2012 → Jan 2017	major depressive disorder	University Hospital, Grenoble	Completed	No outcome recorded
Phase 3	NCT01436175 Background	Feb 2012 → Mar 2014	major depressive disorder	Shire	Terminated	No outcome recorded
Phase 3	NCT01436162 Background	Oct 2011 → Dec 2013	major depressive disorder	Shire	Completed	Missed primary
Phase 3	NCT01360866 Background	Oct 2011 → Apr 2017	major depressive disorder	Otsuka Pharmaceutical Development & Commercialization, Inc.	Completed	No outcome recorded
Phase 3	NCT00789854 Comparator	Nov 2008 → Aug 2009	major depressive disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00435279 Background	Jun 2007 → Jul 2009	insomnia, major depressive disorder	Sumitomo Pharma America, Inc.	Completed	No outcome recorded
Phase 3	NCT00351910 Background	May 2006 → Apr 2007	major depressive disorder	AstraZeneca	Completed	Met primary
Phase 3	NCT00086190 Comparator	Jun 2005 → Nov 2009	Parkinson disease, major depressive disorder	University of Rochester	Completed	No outcome recorded
Phase 3	NCT00074815 Background	Sep 2003 → Nov 2009	obsessive-compulsive disorder	Duke University	Completed	No outcome recorded
Phase 4	NCT04961190 Comparator	May 2022 → Nov 2026 expected	post-traumatic stress disorder	University of Pennsylvania	Active not recruiting	No outcome recorded
Phase 4	NCT04597190 Comparator	Jun 2020 → Aug 2024	post-traumatic stress disorder	University of Washington	Completed	No outcome recorded
Phase 4	NCT05569031 Comparator	Jan 2019 → Dec 2021	substance withdrawal syndrome	Zagazig University	Completed	No outcome recorded
Phase 4	NCT02714400 Comparator	Mar → Jul 2016	obstructive sleep apnea syndrome	University of California, San Diego	Completed	No outcome recorded
Phase 4	NCT02407704 Background	Mar 2015 → Nov 2016	major depressive disorder	Kirk Erickson, PhD	Completed	No outcome recorded
Phase 4	NCT02346682 Comparator	Feb 2015 → Jun 2017	major depressive disorder	Zhejiang Provincial Tongde Hospital	Unknown	No outcome recorded
Phase 4	NCT02350985 Comparator	Jan → Sep 2014	migraine disorder	Haseki Training and Research Hospital	Completed	No outcome recorded
Phase 4	NCT01824433 Comparator	Mar 2013 → Mar 2017	major depressive disorder	Capital Medical University	Completed	No outcome recorded
Phase 4	NCT01764867 Comparator	Jun 2012 → Oct 2014	major depressive disorder	Shanghai Mental Health Center	Unknown	No outcome recorded
Phase 4	NCT01569685 Comparator	Apr 2012 → Oct 2014	depressive disorder, post-traumatic stress disorder	Charlotte Sonne	Completed	No outcome recorded
Phase 4	NCT01443520 Comparator	Oct 2011 → Jan 2012	—	Turku University Hospital	Completed	No outcome recorded
Phase 4	NCT01658228 Background	Sep 2011 → Jan 2016	cognitive impairment with or without cerebellar ataxia, depressive disorder	New York State Psychiatric Institute	Completed	Missed primary
Phase 4	NCT01028508 Comparator	Jan 2010 → Sep 2015	depressive disorder	Icahn School of Medicine at Mount Sinai	Completed	No outcome recorded
Phase 4	NCT01305707 Comparator	Jul 2009 → Jul 2014	major depressive disorder	Hospital Universitari de Bellvitge	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT00926835 Comparator	May 2009 → May 2015	major depressive disorder	Ministry of Health & Welfare, Korea	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT00253266 Background	Apr 2008 → Apr 2014	depressive disorder	Max-Planck-Institute of Psychiatry	Completed	No outcome recorded
Phase 4	NCT00590863 Comparator	Mar 2008 → Sep 2009	major depressive disorder	National Institute of Mental Health (NIMH)	Completed	No outcome recorded
Phase 4	NCT00627887 Background	Jan 2008 → May 2012	major depressive disorder	Örebro County Council	Completed	No outcome recorded
Phase 4	NCT00150839 Comparator	Mar 2006 → Dec 2009	major depressive disorder	University of Erlangen-Nürnberg Medical School	Completed	No outcome recorded
Phase 4	NCT00200902 Comparator	Aug 2005 → Jun 2009	depressive disorder	University of California, Los Angeles	Completed	No outcome recorded
Phase 4	NCT00183274 Comparator	Jan 2004 → Sep 2009	anxiety disorder	University of Pennsylvania	Completed	No outcome recorded
Phase 4	NCT00177671 Background	Dec 2003 → Sep 2009	dementia, major depressive disorder	University of Pittsburgh	Completed	Missed primary
Phase 4	NCT00759122 Comparator	Nov 2002 → Nov 2005	major depressive disorder	University of California, Los Angeles	Completed	No outcome recorded
Phase 4	NCT00644982 Comparator	Oct 2002 → Sep 2003	major depressive disorder	Viatris Inc.	Completed	No outcome recorded
Phase 4	NCT00759317 Comparator	Jun 2001 → Aug 2002	depressive disorder	University of California, Los Angeles	Completed	No outcome recorded
Phase 4	NCT00792168 Comparator	Nov 1996	major depressive disorder	University of California, Los Angeles	Completed	No outcome recorded
—	NCT07230171 Comparator	Sep 2025 → Jun 2027 expected	fibromyalgia	Beijing Tiantan Hospital	Recruiting	No outcome recorded
—	NCT07025590 Comparator	Apr 2025 → Dec 2026 expected	cardiovascular disorder, mixed anxiety and depressive disorder	Guangdong Provincial People's Hospital	Recruiting	No outcome recorded
—	NCT06278038 Comparator	Feb → Nov 2024	major depressive disorder	First Affiliated Hospital of Zhejiang University	Completed	No outcome recorded
—	NCT06659094 Background	Aug 2023 → Aug 2025	obsessive-compulsive disorder	Shanghai Mental Health Center	Completed	No outcome recorded
—	NCT04664088 Comparator	Jan 2021 → Jun 2023	migraine disorder	Affiliated Hospital of Jiaxing University	Unknown	No outcome recorded
—	NCT02655354 Background	Oct 2015 → Nov 2019	alcohol-related disorders, brain injury, cognitive impairment with or without cerebellar ataxia, depressive disorder +1	University of Washington	Completed	No outcome recorded
—	NCT01944657 Comparator	Sep 2013 → Dec 2015	major depressive disorder	Sheppard Pratt Health System	Withdrawn	No outcome recorded Stop: Enrollment
—	NCT01896349 Background	Apr 2013 → Aug 2014	—	Hospital de Clinicas de Porto Alegre	Unknown	No outcome recorded
—	NCT01962753 Background	May 2012 → Jan 2020	major depressive disorder	University Hospital, Tours	Completed	No outcome recorded
—	NCT01609348 Comparator	Apr 2012 → Dec 2016	Alzheimer disease, depressive disorder	Johns Hopkins University	Completed	No outcome recorded
—	NCT01488266 Comparator	Nov 2011 → Jan 2013	major depressive disorder	Korea University	Unknown	No outcome recorded
—	NCT01418209 Comparator	Nov 2011 → Jan 2013	—	Fred Hutchinson Cancer Center	Completed	No outcome recorded
—	NCT00944996 Comparator	Jun 2009 → Jun 2010	major depressive disorder	Tirat Carmel Mental Health Center	Completed	No outcome recorded
—	NCT00564278 Background	Feb 2008 → Aug 2013	depressive disorder	New York State Psychiatric Institute	Completed	No outcome recorded
—	NCT00817011 Comparator	Apr 2006 → Dec 2016	depressive disorder	Samsung Medical Center	Unknown	No outcome recorded
—	NCT00817375 Comparator	Feb 2003 → Dec 2018	depressive disorder	Samsung Medical Center	Unknown	No outcome recorded
—	NCT01228357 Comparator	Feb 2003 → Dec 2018	depressive disorder	Samsung Medical Center	Unknown	No outcome recorded
—	NCT00159146 Comparator	Aug 2002 → Sep 2007	major depressive disorder	Hillerod Hospital, Denmark	Terminated	No outcome recorded
—	NCT00909155 Comparator	Jul 2002 → Dec 2009	major depressive disorder	University of Wisconsin, Madison	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 11

Date	Issuer	Release
2026-03-23	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Regulatory Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD) viatris.com ↗ Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Effexor ® SR 37.5 mg / 75 mg capsules (venlafaxine hydrochloride), a serotonin-noradrenaline reuptake inhibitor (SNRI), for the treatment of adults with generalized anxiety disorder (GAD).
2025-11-11	Zydus Lifesciences Limited	Regulatory Zydus receives approval from China’s NMPA for Venlafaxine Extended-Release Capsules, 75 mg and 150 mg zyduslife.com ↗ Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received approval from the National Medical Products Administration (NMPA), China for Venlafaxine Extended-Release (ER) Capsules, 75 mg and 150 mg.
2025-04-21	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Regulatory Viatris Files Supplemental New Drug Applications to Japan's Ministry of Health, Labor and Welfare for the Approval of EFFEXOR® for the Treatment of Generalized Anxiety Disorder viatris.com ↗
2024-10-09	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Results Viatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese Adults with Generalized Anxiety Disorder (GAD) viatris.com ↗ The study achieved its primary objective of superiority of anxiolytic effects of venlafaxine compared to placebo at 8 weeks, based on the change in the Hamilton Anxiety Rating Scale (HAM-A) total score from baseline (two-sided p-value=0.012).
2022-08-31	Zydus Lifesciences Limited	Regulatory Zydus receives two final approvals from the USFDA zyduslife.com ↗ Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) has received final approval from the United States Food and Drug Administration (USFDA) to market Venlafaxine Extended -Release Tablets, US P 37.5 mg, 75 mg, 150 mg and 225 mg.
2011-04-19	Wockhardt	Regulatory WOCKHARDT RECEIVES US FDA APPROVAL FOR GENERIC VERSION OF EFFEXOR XR® CAPSULES wockhardt.com ↗ Wockhardt receives US FDA approval for generic version of Effexor XR® capsules
2010-07-01	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Introduces First Generic Effexor XR® Capsules in the United States; Awarded 180-Day Period of Marketing Exclusivity tevapharm.com ↗ As the first company to file an Abbreviated New Drug Application (ANDA) containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity.
2010-06-29	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Announces Approval of Generic Effexor XR® tevapharm.com ↗ Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today U.S. Food and Drug Administration (FDA) approval of Venlafaxine HCl ER Capsules, the Company's generic version of Wyeth's antidepressant Effexor XR®.
2008-11-27	Sun Pharmaceutical Industries, Inc.	Regulatory Sun Pharma update on ANDA for generic Effexor XR: USFDA grants Osmotica's citizen petition sunpharma.com ↗
2007-10-18	Impax Laboratories, LLC	Regulatory IMPAX Announces Tentative Approval of Generic Effexor XR(R) amneal.com ↗ IMPAX Laboratories, Inc. (OTC:IPXL) today announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval to the Company's Abbreviated New Drug Application (ANDA) for a generic version of Effexor XR(R) (venlafaxine HCl) 37.5mg, 75mg and 150mg extended release capsules.
2006-08-04	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Announces Final Approval of Venlafaxine HCL Tablets tevapharm.com ↗ Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application ("ANDA") for Venlafaxine Hydrochloride Tablets, 25 mg, 37.5 mg, 50 mg, 75 mg and 100 mg.

All press releases naming this drug 16 releases

Date	Issuer	Release
2026-03-23	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD) viatris.com ↗
2025-11-11	Zydus Lifesciences Limited	Zydus receives approval from China’s NMPA for Venlafaxine Extended-Release Capsules, 75 mg and 150 mg zyduslife.com ↗
2025-04-21	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Viatris Files Supplemental New Drug Applications to Japan's Ministry of Health, Labor and Welfare for the Approval of EFFEXOR® for the Treatment of Generalized Anxiety Disorder viatris.com ↗
2024-10-09	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Viatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese Adults with Generalized Anxiety Disorder (GAD) viatris.com ↗
2022-08-31	Zydus Lifesciences Limited	Zydus receives two final approvals from the USFDA zyduslife.com ↗
2020-01-06	Lannett Company, Inc.	Lannett Launches Venlafaxine ER Tablets And Lidocaine Topical Solution 4% investorroom.com ↗
2018-03-01	Sumitomo Pharma America, Inc.	Pfizer and Sumitomo Dainippon Pharma Commence the Co-Promotion of Serotonin-Norepinephrine Reuptake Inhibitor EFFEXOR SR Capsules sumitomo-pharma.com ↗
2011-04-19	Wockhardt	WOCKHARDT RECEIVES US FDA APPROVAL FOR GENERIC VERSION OF EFFEXOR XR® CAPSULES wockhardt.com ↗
2010-07-01	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Introduces First Generic Effexor XR® Capsules in the United States; Awarded 180-Day Period of Marketing Exclusivity tevapharm.com ↗
2010-06-29	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Approval of Generic Effexor XR® tevapharm.com ↗
2008-11-27	Sun Pharmaceutical Industries, Inc.	Sun Pharma update on ANDA for generic Effexor XR: USFDA grants Osmotica's citizen petition sunpharma.com ↗
2007-10-18	Impax Laboratories, LLC	IMPAX Announces Tentative Approval of Generic Effexor XR(R) amneal.com ↗
2007-10-16	Sun Pharmaceutical Industries, Inc.	Sun Pharma receives will-not-sue covenant on generic Effexor XR ® ANDA sunpharma.com ↗
2006-08-04	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Final Approval of Venlafaxine HCL Tablets tevapharm.com ↗
2005-12-02	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces FTC Will Not File Objections to Effexor® Xr Settlement tevapharm.com ↗
2005-10-18	Teva Branded Pharmaceutical Products R&D, Inc.	Teva and Wyeth Announce Settlement of Effexor Xr® Litigation tevapharm.com ↗

Evidence & citations 24 cited values

Every value below carries the sentence it was read from. 207 sources stand behind the page.

Field	Value	Cited text
Known as	Venlafaxine	“Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR),...” NCT00564278 ↗ 195 “ADT such as citalopram, escitalopram, fluoxetine, sertraline, paroxetine, vilazodone, venlafaxine, desvenlafaxine, duloxetine or bupropion prescribed in accordance with its...” NCT01838876 ↗ “Eligible adults (18-65 years) were assigned to antidepressant monotherapy (escitalopram or venlafaxine extended-release) plus lisdexamfetamine dimesylate-matching placebo...” PMID 28857719 ↗ Aug 2017 “This study is intended to collect data on the efficacy and safety of venlafaxine XR (Efexor XR®) versus SSRIs and conventional antidepressants in depressed patients that...” NCT00474708 ↗ “Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (0.1-0.3 mg/d) Oral, once daily for 8 weeks following an 8 week...” NCT00854100 ↗ “SPD489 20mg, 30mg, 50mg, or 70mg + Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine...” NCT01436175 ↗ “If never taken SSRI or SNRI, commence primary medication arm (SSRI: sertraline, escitalopram or Pregabalin/SNRI: duloxetine, venlafaxine) will be described to patient and will...” NCT04478526 ↗ “Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.” NCT00742573 ↗ “A Sequential, Open Label Study to Compare the Pharmacokinetics, Safety and Tolerability of Ticagrelor and Venlafaxine Given Concomitantly in Healthy Subjects Aged 18 to 45 Years” NCT01350921 ↗ “quantifying the range of concentration to citalopram, escitalopram, sertraline, fluoxetine, paroxetine, fluvoxamine, duloxetine and venlafaxine in mother plasma and breast milk” NCT01796132 ↗ “We made other SSRIs (escitalopram, sertraline) and SNRIs (desvenlafaxine, duloxetine, venlafaxine) our third-line antidepressants, given their negligible effects on weight.” NCT04437485 ↗ Show 185 more sources
Known as	Efexor	“The purpose of this study is to investigate whether Efexor (venlafaxine) is effective in the treatment of functional dyspepsia.” NCT00115362 ↗
Known as	Efexor XR	“This study is intended to collect data on the efficacy and safety of venlafaxine XR (Efexor XR®) versus SSRIs and conventional antidepressants in depressed patients that...” NCT00474708 ↗ 1 “Then, each subject will be randomized to treatment with Efexor XR (first and last two weeks 75 mg 1dd and from the third to the fifth week 75 mg 2dd) or identical placebos for 8 weeks.” NCT00115362 ↗
Known as	Effexor	“The purpose of this study to assess the single-dose relative bioavailability of Actavis Group hf 50 mg venlafaxine hydrochloride tablets with Wyeth Pharmaceuticals (Effexor®)...” NCT00871364 ↗ 14 “The study is a randomized, double-blind, placebo-controlled trial of venlafaxine (a serotonin and norepinephrine reuptake inhibitor, also known as Effexor).” NCT00205491 ↗ “venlafaxine hydrochloride (Effexor) in chronic neuropathic (burning, shock-like, electric) pain after spinal cord injury (SCI).” NCT00167856 ↗ “Venlafaxine (Effexor) works as a mixed serotonin, norepinephrine, and dopamine reuptake inhibitor.” NCT00001483 ↗ “Venlafaxine (Effexor) Extended-Release (XR) comes in capsule form and is taken by mouth.” NCT02407704 ↗ “patients are randomized to receive nortriptyline, venlafaxine (Effexor), or placebo” NCT00045916 ↗ “immediate release (IR) and sustained release (XR) medication venlafaxine (Effexor®)” NCT02005107 ↗ “Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro)” NCT00200902 ↗ “venlafaxine (Effexor and others)” NCT01944657 ↗ “Venlafaxine (Effexor)25-225;” NCT00074815 ↗ “Drug: venlafaxine (Effexor)” NCT00759122 ↗ Show 4 more sources
Known as	EFFEXOR XR	“A Twelve-week, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group, Active Controlled, Escalating Dose Study to Compare the Effects on Sexual Functioning of...” NCT00316160 ↗ 3 “Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR),...” NCT00564278 ↗ “Arm A: to receive venlafaxine hydrochloride 75 mg (Effexor X.R) 75mg once daily from day 1 to day 7 to avoid need of dose tapering .” NCT05875610 ↗ “METHOD: Effexor XR/Novo-venlafaxine XR 75 mg and Celexa/Gen-citalopram 40 mg were studied in a randomized crossover design.” PMID 19653973 ↗ Jul 2009
Known as	Extended-release Venlafaxine	“A Twelve-week, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group, Active Controlled, Escalating Dose Study to Compare the Effects on Sexual Functioning of...” NCT00316160 ↗
Known as	NOVO-Venlafaxine XR	“METHOD: Effexor XR/Novo-venlafaxine XR 75 mg and Celexa/Gen-citalopram 40 mg were studied in a randomized crossover design.” PMID 19653973 ↗ Jul 2009
Known as	VEN ER	“Venlafaxine Extended Release (VEN ER)” NCT00727064 ↗
Known as	Ven-XR	“The purpose of this study is to determine if Venlafaxine Extended Release (Ven-XR) is effective in treating individuals with marijuana addiction and depression.” NCT00131456 ↗
Known as	Venalafaxine hydrochloride	“Drug: Venalafaxine hydrochloride” NCT00167856 ↗
Known as	venlafaxine ER	“This is a phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of venlafaxine ER 75 mg/day (fixed dose)...” NCT01441440 ↗ 1 “venlafaxine ER 75 mg/d or desvenlafaxine 100 mg/d” PMID 19142106 ↗ Feb 2009
Known as	venlafaxine extended release	“Standard dosing with paroxetine, a selectiveserotonin reuptake inhibitor that is FDA approved to treat PTSD and depression, or venlafaxine extended-release, a...” NCT04961190 ↗ 5 “The present study is a non-inferiority comparison of duloxetine 60-120 mg/day and venlafaxine extended-release (XR) 75-225 mg/day for the treatment of adults with generalized...” PMID 18635722 ↗ Jun 2008 “The aim of this study was to assess antidepressant efficacy and safety of venlafaxine extended release in Japanese patients with major depressive disorder (MDD).” PMID 26513202 ↗ Jan 2016 “Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator” NCT02493868 ↗ “Venlafaxine extended-release for depression following spinal cord injury: a randomized clinical trial.” PMID 25607727 ↗ Mar 2015 “single doses of venlafaxine extended release (ER) and desvenlafaxine” PMID 19142106 ↗ Feb 2009
Known as	venlafaxine extended release (XR)	“The objective of the current multisite study was to compare relatively higher doses of sertraline (i.e., 150 mg/day) and venlafaxine extended release (XR) (225 mg/day) in...” PMID 17196045 ↗ Nov 2006 1 “Venlafaxine Extended Release (XR) (Oral Antidepressant)” NCT03434041 ↗
Known as	Venlafaxine HCl	“Venlafaxine HCl is classified as a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) and has been approved by the FDA for the treatment of major depressive disorder.” NCT00735670 ↗
Known as	Venlafaxine HCl ER	“Drug: Venlafaxine HCl ER” NCT04973930 ↗
Known as	Venlafaxine hydrochloride	“For the combination therapy group, participants will receive both pregabalin and venlafaxine (Venlafaxine Hydrochloride Sustained-Release Capsules, Pfizer, Co Kildare,...” NCT07186751 ↗ 6 “Arm A: to receive venlafaxine hydrochloride 75 mg (Effexor X.R) 75mg once daily from day 1 to day 7 to avoid need of dose tapering .” NCT05875610 ↗ “venlafaxine hydrochloride (Effexor) in chronic neuropathic (burning, shock-like, electric) pain after spinal cord injury (SCI).” NCT00167856 ↗ “The serotonin-norepinephrine reuptake inhibitor venlafaxine hydrochloride is used widely as a nonhormonal treatment.” PMID 24861828 ↗ Jul 2014 “Venlafaxine hydrochloride sustained-release capsules 75mg x 14 tablets x 1 case 75-225mg/morning” NCT04207385 ↗ NCT01282801 ↗ NCT01260896 ↗
Known as	Venlafaxine Hydrochloride (generic name)	“Venlafaxine Hydrochloride (generic name)” NCT01282801 ↗ 1 “Venlafaxine Hydrochloride (generic name)” NCT01282814 ↗
Known as	venlafaxine hydrochloride extended-release (XR)	“To determine the efficacy and tolerability of venlafaxine hydrochloride extended-release (XR) for major depressive disorder (MDD) or dysthymic disorder in persons with chronic SCI.” PMID 25607727 ↗ Mar 2015
Known as	Venlafaxine XR	“Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR),...” NCT00564278 ↗ 9 “In this double-blind, multicenter study, bupropion XL, a norepinephrine-dopamine reuptake inhibitor, and venlafaxine XR, a serotonin-norepinephrine reuptake inhibitor, were...” PMID 16974189 ↗ Oct 2006 “This study is intended to collect data on the efficacy and safety of venlafaxine XR (Efexor XR®) versus SSRIs and conventional antidepressants in depressed patients that...” NCT00474708 ↗ “The two medications the investigators are using are: an anti-depressant medication called venlafaxine extended release (venlafaxine XR), which is the generic form of Effexor,...” NCT02181231 ↗ “Subjects will be randomized in a 1:1 ratio to receive either sertraline or venlafaxine XR based on a computer-generated randomized list.” NCT00179283 ↗ “Venlafaxine XR can be selected as the oral antidepressant medication based on investigator's discretion.” NCT03434041 ↗ “Once daily oral dose of venlafaxine XR ranging from 37.5 mg up to 300 mg” NCT00592384 ↗ “Venlafaxine XR is the extended release (XR) version of venlafaxine.” NCT01418209 ↗ “20-60mg of paroxetine daily, or 75-300mg of venlafaxine XR daily” NCT04961190 ↗ “Drug: venlafaxine XR” NCT00644982 ↗
Known as	VLX	“In our experience, venlafaxine (VLX) and escitalopram (ESC) are the two antidepressants best tolerated and least likely to interfere with oncotherapy for patients with MDD and...” NCT04973930 ↗
Known as	VXR	“OBJECTIVE: This study aimed to describe the pharmacokinetics and safety of LDX and venlafaxine extended-release (VXR), alone or combined.” PMID 23512639 ↗ Apr 2013
Action	Inhibit	“Norepinephrine/Serotonin Reuptake Inhibitor (NSRI)” NCT00167856 ↗
Modality	Small molecule	“Venlafaxine is a phenylethylamine derivative” NCT00198250 ↗
Route	Oral	“Patients receive oral venlafaxine once daily for 6 weeks beginning on day 8.” NCT00030914 ↗